A Study of the Relationship between Oxidative Stress and Risk of Developing Hepatocellular Carcinoma in People with Hepatitis B Infection; A Systematic Review Study

Hammadi Nour¹, Chouia Maroua¹, Derouiche Samir¹,²

¹Department of Cellular and Molecular Biology, Faculty of Natural Sciences and Life, University of El Oued, Algeria. ²Laboratory of Biodiversity and Application of Biotechnology in the Agricultural Field, University of El Oued, Algeria.

Abstract

Introduction: Hepatitis B infection is a severe global public health issue. It is the 10th biggest cause of death worldwide. Objective: This review focuses on the relationship between oxidative stress and the risk of developing of acute and chronic hepatitis B complications. Methods: The data were collected by searching Science Direct, Google Scholar, PubMed, Scopus, Springer and National Center for Biotechnology Information (NCBI). The Keywords used as search terms were “Hepatitis B”, “Acute and Chronic hepatitis”, “HBV induced inflammatory reaction”, “hepatitis B and Oxidative stress” and “free radical induced hepatitis B complication”. Results: Chronic infections with chronic active hepatitis, acute or sub-acute hepatic necrosis, cirrhosis, liver failure, and hepatocellular cancer in people with hepatitis B infection are all complications of viral hepatitis. Extrahepatic complications are common in patients with chronic hepatitis infection, including cryoglobulinemia, non-Hodgkin lymphoma, focal lymphocytic sialadenitis, autoimmune thyroiditis, porphyria cutanea tarda, and lichen planus. Wide variations in hepatitis B incubation durations show that the redox state of cells can influence viral activity. Viral replication is more active with more severe oxidative stress, with dispersion from lysed or dead cells. Although the precise mechanisms of ROS participation in the pathogenesis of inflammatory disorders are still debated. Conclusion: Viral activity can be determined by the oxidative stress status of the cells which can be the main cause of the development of hepatocellular carcinoma related to the complications of acute and chronic hepatitis B.

Keywords: Hepatitis B- Oxidative stress- Hepatocellular carcinoma- inflammation

Introduction

Hepatitis B (HBV) infection is a severe global public health issue, with approximately 250 million people afflicted on a long-term basis [1]. It is the 10th biggest cause of death worldwide, accounting about 1.2 million fatalities per year. The prevalence of HBV infection varies significantly among geographic and demographic categories [2]. The area with the highest hepatitis B surface antigen (HBsAg) prevalence of >8% is Western sub-Saharan Africa, followed by Eastern sub-Saharan Africa, Central Asia, Southeast Asia, China and Oceania with a high intermediate prevalence of 5–7%; Latin America, Eastern Europe, North Africa, the Middle East, Turkey, Afghanistan, Pakistan, India and Australia with a low intermediate prevalence of 2–4% and the USA and Canada, Central America, Brazil and Western Europe with a low prevalence of <2% [3]. Different from HCV infection, the annual mortality rate from HBV infection in the USA did not change shown to be cost-saving in countries with high and intermediate endemicity [4]. Apart from exposure prophylaxis through personal protection measures, HBV vaccination should be administered to all unvaccinated individuals traveling to areas with high or intermediate HBsAg prevalence [5]. In viral hepatitis, cellular damage is predominantly determined by
the immune response and, although the pathophysiology is very complex, there are a very large number of data demonstrating that the persistence of infection, the progression of liver damage and carcinogenesis are all steps in which oxidative-mediated pathways are involved [6]. Many of recent landmarks in scientific research have shown that in human beings, oxidative stress has been implicated in the progression of major health problems by inactivating the metabolic enzymes and damaging important cellular components [7], it is as a consequence of increase a reactive oxygen species and decrease in antioxidant defenses in prevalent in many health problems [8]. Reactive oxygen and nitrogen species (ROS, RNS) play a crucial role in the induction and in the progression of liver disease, independently from its etiology [9]. They are involved in the transcription and activation of a large series of cytokines and growth factors that, in turn, can contribute to further production of ROS and RNS [10]. In light of these data, the aim of this review was to identify the role of oxidative stress as factors associated with acute and chronic hepatitis B development or complications.

Methods
The data were collected by searching Science Direct, Google Scholar, PubMed, Scopus, Springer and National Center for Biotechnology Information (NCBI). The Keywords used as search terms were “Hepatitis B”, “Acute and Chronic hepatitis”, “HBV induced inflammatory reaction”, “hepatitis B and Oxidative stress” and “free radical induced hepatitis B complication”.

Shapes of hepatitis B Particle
The hepatitis B virus is difficult to culture, but due to the large quantity of viral particles in sick people’s serum, it was found early on using electron microscopy [11]. Infectious viral particles 40 to 48 nm in diameter, known as Dane particles, corresponding to complete virions, show three forms of structure. They have a core (nucleocapsid containing partly double-stranded DNA coupled with a DNA polymerase) and an envelope and are the least common [12]. Spherical particles or spherules with a diameter of 18 to 25 nm and filaments or tubules with a diameter of 22 nm and a length of 50 to 250 nm that could be aggregate spheres. These latter two pieces are similar to the envelope virus in structure and carry HBsAg [13]. They consist of an envelope consisting of a bilayer lipid and have a diameter of 25 to 27 nm. These non-infectious spherules and filaments are excess products [14].

Acute Infection
A moderate, asymptomatic, and subclinical sickness affects about two-thirds of individuals with acute HBV infection, which generally goes unnoticed [15]. A third of individuals with acute HBV infection have clinical hepatitis symptoms and signs, which can range from mild constitutional symptoms like fatigue and nausea to more severe symptoms like jaundice and, in rare cases, acute liver failure [16]. Acute hepatitis B has a clinical incubation time of 2–3 months, but it can vary from 1–6 months after exposure, with the length of the incubation period corresponding to some extent with the level of virus exposure [17]. A brief pre-icteric or prodromal period of constitutional symptoms such as fever, lethargy, anorexia, nausea, and body aches follows the incubation period. Serum ALT levels rise during this phase, and high levels of HBsAg and HBV DNA are detected. The pre-icteric phase can continue anywhere from a few days to a week and is followed by jaundice or dark urine [18]. The icteric phase of hepatitis B lasts 1–2 weeks and is characterized by a reduction in viral levels. Jaundice goes away after convalescence, although constitutional symptoms can remain for weeks or even months. HBsAg is eliminated, followed by the removal of detectable HBV DNA from serum, during this phase. Acute liver failure affects about 1% of people who have acute hepatitis B and jaundice [19]. Abdominal discomfort, fever, vomiting, and jaundice are common symptoms of fulminant hepatitis, which are often followed by disorientation, confusion, and coma [20]. HBV and HBsAg As liver failure progresses, DNA levels drop rapidly, and some patients are HBsAg-negative by the time hepatic coma sets in [21]. Acute liver failure caused by hepatitis B requires careful therapy and monitoring, and patients should be transferred to a tertiary medical hospital that offers liver transplantation as soon as possible [22].

Chronic Infection
The course of chronic hepatitis B is unpredictable and ever-changing. HBeAg, HBsAg, and HBV DNA are frequently present in high titers early in infection, and serum aminotransferase levels are mild to moderately elevated [23]. The severity of chronic hepatitis has a direct relationship with the patient’s overall prognosis. The 5-year survival rate for people with severe chronic hepatitis and cirrhosis is around 50%. Many patients with chronic hepatitis (elevated ALT, inflammation, and/or fibrosis on liver biopsy) are asymptomatic or have vague symptoms including fatigue and mild right upper quadrant discomfort [24]. Acute exacerbations of chronic hepatitis with substantially increased serum ALT can occur in patients with chronic hepatitis. This scenario is more common in those with chronic hepatitis B who do not have HBeAg [25]. Anti-HBc IgM is a valuable marker for distinguishing between acute hepatitis B and chronic hepatitis B with a flare, as mentioned in the previous section. Anti-HBc of the IgM class, on the other hand, is occasionally found in patients with chronic hepatitis B who are experiencing an exacerbation [26]. Alpha-fetoprotein (AFP), which is regarded as a marker for HCC, is frequently raised in tandem with ALT during acute exacerbation. It is uncommon, however, to exceed 400 ng/mL [27]. The development of HCC should be suspected in patients with AFP levels significantly higher than this. An estimated one-third of people with chronic HBV infection may develop cirrhosis, end-stage liver disease, or HCC as a long-term consequence of the infection [28]. The determinants of outcome of chronic hepatitis B appear to be both viral (HBV DNA levels, HBV genotype, some HBV DNA patterns) and host-specific (age, gender, genetic background, immune status) [29].
Complications of Viral Hepatitis B

Chronic infections with chronic active hepatitis, acute or sub-acute hepatic necrosis, cirrhosis, liver failure, and hepatocellular cancer in people with hepatitis B or C infection are all complications of viral hepatitis [30]. Patients with hepatitis B are at a high risk of acquiring chronic infection and hepatocellular carcinoma, which accounts for 45 percent of primary liver cancer worldwide. About 1% of patients will suffer fulminant hepatic failure, with an 80 percent death rate [31]. About 75 to 85 percent of people with hepatitis C acquire chronic infection, and about 20% develop cirrhosis and eventually hepatocellular cancer [32]. Cirrhosis can lead to a variety of problems, such as hepatic encephalopathy, portal hypertension, ascites, spontaneous bacterial peritonitis, variceal hemorrhage, hepatorenal syndrome [33]. Extrahepatic complications are common in patients with chronic hepatitis C infection, including cryoglobulinemia, which can cause a rash, vasculitis, and glomerulonephritis due to immune complex deposition in the small vessels, non-Hodgkin lymphoma, focal lymphocytic sialadenitis, autoimmune thyroiditis, porphyria cutanea tarda, and lichen planus [34].

Discussion

Oxidative stress refers to the imbalance between the production of reactive species and antioxidant defence. According to Sies oxidative stress is “a disturbance in the pro-oxidant-antioxidant balances in favour of the former, leading to serious damage” [35]. Oxidative stress focuses the attention of worldwide researchers for its damaging effects on the human body [36] (Anand. 2014), and essential for life and also responsible for the death of a cell. In organisms including human’s reactive oxygen species (ROS) and free radicals are produced during metabolic and immune system function [37]. Molecular oxygen (O$_2$) has ability to un-pair and leave free radicals which are unstable and highly reactive leads to formation of ROS [38]. Until the cellular redox equilibrium is disrupted, intracellular parasitic viruses may stay clinically dormant and without reactivation within host cells [39]. Wide variations in hepatitis B incubation durations show that the redox state of cells can influence viral activity. Viral replication is more active with more severe oxidative stress, with dispersion from lysed or dead cells [40]. Viruses use the host cell’s synthetic processes to multiply, altering the endoplasmic reticulum and mitochondria’s normal physiological biochemistry, resulting in increased ROS generation and antioxidant depletion [41]. Although the precise mechanisms of ROS participation in the pathogenesis of inflammatory disorders are still debated, ROS play a significant role in the pathogenesis of inflammatory diseases [42]. Parenchymal damage ranges from asymptomatic anicteric hepatitis to necroinflammatory hepatitis (acute, recurring, or chronic), cirrhosis, and cancer as a result of the resulting redox imbalance and oxidative stress (OS) [9]. The hepatitis B virus depletes antioxidants, and high levels of peroxidation products have a secondary effect on immunological cells. Chronic inflammation, iron excess, liver damage, and HCV-encoded proteins all contribute to systemic oxidative stress, which is most likely produced by a combination of chronic inflammation, iron overload, liver damage, and HCV-encoded proteins [43]. The increased generation of reactive oxygen and nitrogen species, together with the decreased antioxidant defense, promotes the development and progression of hepatic and extrahepatic complications of HCV infection [44]. Although HBV causes hepatitis, it appears to be particularly effective at causing oxidative stress, implying that the virus has its own oxidative stress-inducing mechanisms [45]. In sinusoids and areas of parenchymal necrosis, immunohistochemical examinations of biopsies from patients with acute hepatitis revealed the presence of vascular cell adhesion molecules ICAM-1, ELAM-1, and VCAM-1, as well as T-cell homing receptor [46]. This adds to our understanding of cytokine-induced upregulation of adhesiveness and recruitment of cytotoxic CD8 lymphocytes, followed by T-cell-mediated cell death via the release of cytotoxic substances like perforin and proteases (granzymes) or apoptosis via the FAS/Apo-1/CD 95 receptor system and mitochondrial dysfunction [47]. Apoptosis is induced by viral infection (in human liver diseases Councilman Bodies are the expression of apoptosis). This allows the virus to suppress or diminish the host immune response, allowing viral reproduction and spread [48]. TNF-, TGF-ß, IFN-ß, and IL-2 pathways influence apoptosis in HBV core, and these cytokines also alter the progression of liver injury to chronicity. The immune-mediated response of Th0/Th1 cytokines like IL-4 and IL-10, on the other hand, protects against the persistence of viruses and the formation of fibrosis [49].

In conclusion, Viral activity can be determined by the state of oxidative stress of cells, which can be the main cause of the development and complications of acute and chronic hepatitis B, and the most dangerous of them remains related to the emergence of complications related to liver cancer, and therefore it is necessary to take into account these phenomena in any approved treatment program, which may contribute to the prevention of Hepatitis B-related liver cancer and its complications.

Authors’ contribution

CM participated in search and analysis of the paper. SD is the corresponding author. CM, HN and SD conducted the final edit and finalized the manuscript. All authors read and signed the final paper.

Conflicts of interest

The authors declare that they have no competing interests.

Ethical issues

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by the authors.

Funding/Support

None.
References

1. Ganem D, Prince AM. Hepatitis B virus infection--natural history and clinical consequences. The New England Journal of Medicine. 2004 03;11:350(11):1118-1129. https://doi.org/10.1056/NEJMra031087

2. Derouiche S. Prevalence and Epidemiological Study of hepatitis B and C patients admitted to BEN AMOR DJILANI hospital in El Oued, Algeria. Pharmaceutical and Biosciences Journal. 2021 06;07;41-48. https://doi.org/10.20510/pbj/19/3/1500

3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012 09;30(12):2212-2219. https://doi.org/10.1016/j.vaccine.2011.12.116

4. Bukh J, Wantzin P, Krogsgaard K, Knudsen F, Purcell RH, Miller RH. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. Copenhagen Dialysis HCV Study Group. The Journal of Infectious Diseases. 1993 Dec;168(6):1343-1348. https://doi.org/10.1093/infdis/168.6.1343

5. Mast E, Weinbaum C, Fiore A, Alter M, Bell B, Finelli L, Rodewald L, Douglas J, Janssen R, Ward J. Comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recomm Rep. 2006;5(5):1-33.

6. Rizzetto M, Purcell R, Gerin J, Verme G. Viral hepatitis and liver disease. Edizioni Minerva Medica. 1997. pp. 267-70.

7. Samir Derouiche, Anfal Djouadi. an evaluation of stress oxidative and serum electrolytes in female hypothyroid patients. Int J Biol Med Res. 2017; 8(1): 5861-5865.

8. Tan BL, Norhaizan ME, Liew W, Sulaiman Rahman H. Acetylated Hepatitis B virus DNA: a DNA polymorphism in age-related diseases. Asian Journal of Biological Sciences. 2019 02;12:192-198. https://doi.org/10.3923/ajbs.2019.192.198

9. Loguercio C, Federico A. Oxidative stress in viral and alcoholic hepatitis. Free Radical Biology & Medicine. 2003 01;1;34(1):1-10. https://doi.org/10.1016/s0891-5849(02)01167-x

10. Derouiche S, Asma S, Om R. Risk of Metribuzin (Triazine Herbicide) on Hematological and Renal Structure and Function of Pregnant Rabbits. Asian Journal of Biological Sciences. 2019 02;01;12:192-198. https://doi.org/10.3923/ajbs.2019.192.198

11. Gerlich WH. Medical Virology of Hepatitis B: how it began and where we are now. Virology Journal. 2013 07;20;1(1):239. https://doi.org/10.1186/1743-422X-10-239

12. Hu J, Liu K. Complete and Incomplete Hepatitis B Virus Particles: Formation, Function, and Application. Viruses. 2017 03;21;9(3):656. https://doi.org/10.3390/v9030056

13. Patient R, Hourieux C, Roingeard P. Morphogenesis of hepatitis B virus and its subviral envelope particles. Cellular Microbiology. 2009 Nov;11(11):1561-1570. https://doi.org/10.1111/j.1462-5882.2009.01363.x

14. Tiollais P, Pourcel C, Dejean A. The hepatitis B virus. Nature. 1985 Oct;317(6037):489-495. https://doi.org/10.1038/317489a0

15. Robotis J, Boleti H. Viral Hepatitis. xPharm: The Comprehensive Pharmacology Reference. 2007;1-10. https://doi.org/10.1016/B978-008055232-3.60928-6

16. Burns GS, Thompson AJ. Viral hepatitis B: clinical and epidemiological characteristics. Cold Spring Harbor Perspectives in Medicine. 2014 Oct 30;4(12):a024935. https://doi.org/10.1101/cshperspect.a024935

17. Krajden M, McNabb G, Petric M. The laboratory diagnosis of hepatitis B virus. The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale. 2005 03;16(2):65-72. https://doi.org/10.1155/2005/450574

18. Ahmad J, Cases J. Hepatitis and Transplant Hepatology. 2010 07;3:121-307. https://doi.org/10.1016/j.hpt.2010.07.002

19. Stillman AE. Jaundice. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition. Boston: Butterworths; 1990. Chapter 87. Available from: https://www.ncbi.nlm.nih.gov/books/NBK4143/

20. Toma D, Lazar O, Bontas E. Acute Liver Failure. Liver Diseases. 2019 07;10;3:369-380. https://doi.org/10.1016/j.978-3-03-24432-3.32

21. Yang S, Lu S, Lee C, Hu T, Wang J, Hung C, Changchien C, Chen C. Combining the HBsAg decline and HBV DNA levels predicts clinical outcomes in patients with spontaneous HBeAg seroconversion. Hepatology International. 2013 06;7(2):489-499. https://doi.org/10.1016/s12072-012-9383-3

22. Manka P, Verheyen J, Gerken G, Canbay A. Liver Failure due to Acute Viral Hepatitis (A-E). Visceral Medicine. 2016 04;32(2):80-85. https://doi.org/10.1159/000444915

23. Karra VK, Chowdhury SJ, Ruttala R, Polipalli SK, Kar P. Clinical Significance of Quantitative HBsAg Titres and its Correlation With HBV DNA Levels in the Natural History of Hepatitis B Virus Infection. Journal of Clinical and Experimental Hepatology. 2019 06;9(3):209-215. https://doi.org/10.1016/j.jchep.2016.07.002

24. Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World Journal of Gastroenterology : WJG. 2014 08 28;20(32):11033-11035. https://doi.org/10.3748/wjg.v20.i32.11033

25. Puri P. Acute Exacerbation of Chronic Hepatitis B: The Dilemma of Differentiation from Acute Viral Hepatitis B. Journal of Clinical and Experimental Hepatology. 2013 Dec;3(4):301-312. https://doi.org/10.1016/j.jchep.2013.08.014

26. Park JW, Kwak KM, Kim SE, Jang MK, Kim DJ, Lee MS, Kim HS, Park CK. Differentiation of acute and chronic hepatitis B in IgM anti-HBc positive patients. World Journal of Gastroenterology : WJG. 2015 04 07;21(13):3953-3959. https://doi.org/10.3748/wjg.v21.i13.3953

27. Patil M, Sheth KA, Adarsh CK. Elevated alpha fetoprotein, no hepatocellular carcinoma. Journal of Clinical and Experimental Hepatology. 2016 09;6(3):209-215. https://doi.org/10.1016/j.jchep.2016.07.002

28. AlSalloom AA. An update of biochemical markers of hepatocellular carcinoma. Int J Health Sci (Qassim). 2016;10(1):121-36.

29. Spanenberg HC, Thimm R, Blum HE. Serum markers of hepatocellular carcinoma. Seminars in Liver Disease. 2006 Nov;26(4):385-390. https://doi.org/10.1055/s-2006-951606

30. Butler DC, Lewin DN, Batalis NI. Differential Diagnosis of Hepatic Necrosis Encountered at Autopsy. Academic Forensic Pathology. 2018 06;8(2):256-295. https://doi.org/10.1016/j.jceh.2018.03.024

31. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012 05;142(6):1264-1273.e1. https://doi.org/10.1053/j.gastro.2011.12.061

32. Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. International Journal of Medical Sciences. 2006;3(2):47-52. https://doi.org/10.7150/ijms.3.47

33. Poorod FF. Presentation and complications associated with cirrhosis of the liver. Current Medical Research and
Opinion. 2015 05;31(5):925-937. https://doi.org/10.1185/03007995.2015.1021905
34. Zeuzem S, Bechstein WO. Viral Hepatitis and Its Complications. Visceral Medicine. 2016 04;32(2):78. https://doi.org/10.1159/000445984
35. Derouiche S, Atoussi N, Guediri S. Assessment of Hematological Parameters, Enzymes Activities, and Oxidative Stress Markers in Salivary and Blood of Algerian Breast Cancer Patients Receiving Chemotherapy. J Biochem Tech. 2019; 10(4): 50-58.
36. Anand K, Humaira F. (2014). “Evaluation of the effect of hydrogen peroxide(H2O2) on haemoglobin and the protective effect of glycine” International journal of science & Technoledge, 2014 ; 2(2) :36-41.
37. Sara C, Ouidad A, Islam B, Yousra GI, Samir D. The effect of Chronic Tobacco smoking on Atherosgen index and Cardiovascular diseases risk in El-Oued (Algeria) Men. Asian Journal of Research in Chemistry. 2020 Dec 08;13(6):489-493. https://doi.org/10.5958/0974-4150.2020.00086.3
38. Derouiche S. Current Review on Herbal Pharmaceutical improve immune responses against COVID-19 infection. Res J Pharm Dosage Forms Tech. 2020; 12(3): 181-184.
39. Dutta NK, Karakousis PC. Latent tuberculosis infection: myths, models, and molecular mechanisms. Microbiology and molecular biology reviews: MMBR. 2014 09;78(3):343-371. https://doi.org/10.1128/MMBR.00010-14
40. Esrefoglu M. Oxidative Stress and Benefits of Antioxidant Agents in Acute and Chronic Hepatitis. Hepatitis Monthly. 2012 03;12(3):160-167. https://doi.org/10.5812/ hepatmon.837
41. Nita M, Grzybowski A. The Role of the Reactive Oxygen Species and Oxidative Stress in the Pathomechanism of the Age-Related Ocular Diseases and Other Pathologies of the Anterior and Posterior Eye Segments in Adults. Oxidative Medicine and Cellular Longevity. 2016;2016:3164734. https://doi.org/10.1155/2016/3164734
42. Chetehouna S, Atoussi O & Derouiche S. () Biological Activity and Toxicological Profile of Zinc Oxide Nanoparticles Synthesized by Portulaca oleracea (L) Leaves Extract. Adv Nanomed Nanotechnol Res. 2020; 2(2): 125-133.
43. Gammoh NZ, Rink L. Zinc in Infection and Inflammation. Nutrients. 2017 06 17;9(6):E624. https://doi.org/10.3390/nu9060624
44. Lozano-Sepulveda SA, Bryan-Marrugo OL, Cordova-Fletes C, Gutierrez-Ruiz MC, Rivas-Estilla AM. Oxidative stress modulation in hepatitis C virus infected cells. World Journal of Hepatology. 2015 Dec 18;7(29):2880-2889. https://doi.org/10.4254/wjh.v7.i29.2880
45. Ivanov AV, Valuev-Elliston VT, Tyurina DA, Ivanova ON, Kochetkov SN, Bartosch B, Isagullants MG. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. Oncotarget. 2016 Dec 11;8(3):3895-3932. https://doi.org/10.18632/oncotarget.13904
46. Halacheva K, Gulubova MV, Manolova I, Petkov D. Expression of ICAM-1, VCAM-1, E-selectin and TNF-alpha on the endothelium of femoral and iliac arteries in thromboangiitis obliterans. Acta Histochemica. 2002;104(2):177-184. https://doi.org/10.1076/0065-1281-00621
47. Demers KR, Reuter MA, Betts MR. CD8(+) T-cell effector function and transcriptional regulation during HIV pathogenesis. Immunological Reviews, 2013 07;254(1):190-206. https://doi.org/10.1111/imr.12069
48. Kumar N, Sharma S, Barua S, Tripathi BN, Rouse BT. Virolological and Immunological Outcomes of Coinfections. Clinical Microbiology Reviews. 2018 Oct;31(4):e00111-17.